Skip to main content
. Author manuscript; available in PMC: 2023 Jul 27.
Published in final edited form as: Cell. 2023 Jul 5;186(15):3148–3165.e20. doi: 10.1016/j.cell.2023.06.002

Figure 2. Endogenous tumor-infiltrating T cells show transcriptional changes associated with enhanced anti-tumor activity in response to CAR T-vax therapy.

Figure 2.

(A) Enumeration of intratumoral host T-cells in tumor-bearing mice (n=5) post CAR T ± vax treatment.

(B-G) Tumor-bearing mice were treated with CAR T ± vax, TILs were isolated for scRNA-seq.

(B) Experimental setup/timeline. Created with BioRender.com.

(C) UMAP of endogenous T-cells obtained from tumors.

(D) Curated clusters based on signature gene expression.

(E) Stacked charts showing proportions of each T-cell cluster.

(F) Dot plots showing differential expression of signature genes in endogenous CD8+ CTLs or CD4+ Th cells.

(G) Cytotoxicity score of endogenous p15E-specific TILs and TILs of unknown specificity.

All mice bear EGFRvIII+CT-2A tumors. Error bars are mean ± 95% CI, ****p<0.0001; **, p<0.01; n.s., not significant by Student’s t-test for A, by two-sided Wilcoxon rank-sum test for G.